GlassScriptPhysician profile
Victor A Klimas
NPI 1801879184
$1,787.55
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $515 · 2020: $145 · 2021: $389 · 2022: $342 · 2023: $166 · 2024: $232.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $342 · Education: $55.15.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $342.18 |
| Education | $55.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $299.44 | 2019-2022 | |
| Baxter Healthcare | $177.13 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $161.75 | 2022-2023 | |
| Glaxosmithkline, LLC. | $150.58 | 2021-2024 | Benlysta |
| Amgen INC. | $138.04 | 2019-2024 | Tavneos, Krystexxa |
| Otsuka America Pharmaceutical, INC. | $114.11 | 2019-2024 | Jynarque |
| Vifor Pharma, INC. | $110.88 | 2019-2020 | |
| Nxstage Medical, INC. | $99.17 | 2022 | |
| Akebia Therapeutics INC | $88.55 | 2020-2023 | Auryxia |
| Horizon Therapeutics Plc | $85.66 | 2019-2021 | |
| Fresenius USA Marketing, INC. | $73.17 | 2019-2023 | Velphoro |
| Opko Pharmaceuticals, LLC | $69.04 | 2019-2024 | Rayaldee |
| Ardelyx, INC. | $55.73 | 2024 | Ibsrela |
| Lilly USA, LLC | $34.37 | 2024 | Jardiance |
| Mallinckrodt Hospital Products INC. | $28.22 | 2023 | Acthar |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $23.72 | 2023 | |
| Alexion Pharmaceuticals, INC. | $18.41 | 2021 | |
| Novartis Pharmaceuticals Corporation | $17.78 | 2019 | |
| Biomerieux INC | $17.58 | 2019 | |
| Calliditas Therapeutics US INC. | $15.60 | 2022 | |
| Athena Bioscience, LLC | $8.62 | 2024 | Nexiclon Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Klimas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.